Background: One of the leading causes of death in the United States is hepatic
fibrosis. For the treatment of liver disease, bone marrow mesenchymal stem cells
have been advocated.fibrosis. Different types of fibrosis may be alleviated by
simvastatin. organs.BM-MSCs and BM-MSCs were compared in the research. as
well as simvastatin for the treatment of carbon-induced liver fibrosis
tetrachloride. Methods: Fifty rats were divided into three groups: CCl4 was
administered into rats in groups II and III to induce fibrous liver disease. CCL4
was injected into the rats in Group III. BM-MSCs are given intravenously in
group IV, which consists of one dosage. CCL4 was injected into the rats, and
they were subsequently administered simvastatin orally once daily for Eight
months. Participants in Group V were administered BM-MSC as well as
simvastatin. Blood samples were collected at the conclusion of the experiment.
collected and liver tissues were processed for biochemical examination
histological and immunohistochemical analysis CCL4 was the result.
There was a large increase in liver enzymes and the destruction of normal hepatic structures, as
well as a considerable rise in the mean area percentage of collagen fibre deposition and TGFexpression levels. There was an improvement in liver enzymes and histological structure,
however the anti-fibrotic impact of BM-MSC was superior than the anti-fibrotic effect of
simvastatin. The combination of BM- MSC and simvastatin had a more powerful anti-fibrotic
impact and protected liver tissue's histological structure than simvastatin alone.
Conclusion: The combination of BM-MSCs and simvastatin improves liver fibrosis produced
by CCl4 therapy
Liver fibrosis, CCL4, BM-MSCs, simvastatin, TGF- are some of the key terms